PRESSRELEASES
24 February, 2026
Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)
The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.
READ MORE19 February, 2026
Nanexa publishes year-end report and Q4 report 2025
The year ended strongly with an important milestone; the license and option agreement with Moderna, which is an important validation of our technology and has created favourable conditions for 2026 and beyond
READ MORELATEST REPORTS
PRESENTATIONS
19 February 2026
Q4 report commentary with CEO David Westberg and Chairman of the Board Göran Ando
11 December 2025
Nanexa and Moderna enter into license and option agreements
6 November 2025
Q3 report commentary with CEO David Westberg
Read the presentation MEET NANEXA
23 - 25 Mar, 2026
David Westberg, CEO, will participate in BIO-Europe in Lisbon, Portugal on 23-25 March
24 Mar, 2026
Kristine Bäck, Director of Project Management, will speak at COG Nordics in Malmoe, Sweden on 24 March
22 - 25 Jun, 2026